Isomorphic Labs is an AI-first drug design and development company that transforms drug discovery to design and evaluate new medicines.
Isomorphic Labs has raised $2.1B in total funding. The most recent round was Series B. The last funding was announced in May 2026.
Isomorphic Labs's investors include Temasek Holdings, Thrive Capital, Alphabet, CapitalG, MGX.
Isomorphic Labs is headquartered in London, United Kingdom.
Isomorphic Labs is an AI-first drug design and development company that transforms drug discovery to design and evaluate new medicines.
Isomorphic Labs is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Isomorphic Labs — Funding & Investors." VCBacked, May 12, 2026, https://www.vcbacked.co/company/isomorphic-labs. Accessed July 19, 2026.
VCBacked. (2026). Isomorphic Labs — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/isomorphic-labs
{{cite web |title=Isomorphic Labs — Funding & Investors |url=https://www.vcbacked.co/company/isomorphic-labs |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated